GRAIL Takes $1.1B Impairment Charge on Galleri Test
Ticker: GRAL · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1699031
Sentiment: bearish
Topics: impairment, strategic-shift, product-discontinuation
TL;DR
GRAIL booked a $1.1B impairment charge, ditching the Galleri test for asymptomatic folks in the US.
AI Summary
GRAIL, Inc. reported a material impairment charge of approximately $1.1 billion on June 24, 2024. This charge is primarily related to the company's decision to discontinue its Galleri test for asymptomatic individuals in the U.S. commercial market. The impairment reflects the reduced future economic benefits expected from the related intangible assets.
Why It Matters
This significant impairment charge indicates a strategic shift for GRAIL, potentially impacting its future revenue streams and market position for its flagship product.
Risk Assessment
Risk Level: medium — The substantial impairment charge suggests significant challenges or a strategic pivot, which could impact investor confidence and future financial performance.
Key Numbers
- $1.1B — Material Impairment Charge (Reflects write-down of assets due to discontinuation of Galleri test for asymptomatic individuals.)
Key Players & Entities
- GRAIL, Inc. (company) — Registrant
- Galleri test (product) — Discontinued product
- $1.1 billion (dollar_amount) — Material impairment charge
- June 24, 2024 (date) — Date of earliest event reported
FAQ
What is the primary reason for the material impairment charge?
The material impairment charge of approximately $1.1 billion is primarily due to GRAIL's decision to discontinue the Galleri test for asymptomatic individuals in the U.S. commercial market.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 24, 2024.
What is the exact amount of the impairment charge?
The filing indicates a material impairment charge of approximately $1.1 billion.
What product is associated with this impairment charge?
The impairment charge is related to GRAIL's Galleri test.
What is GRAIL, Inc.'s principal executive office address?
GRAIL, Inc.'s principal executive offices are located at 1525 O'Brien Drive, Menlo Park, California 94025.
Filing Stats: 752 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2024-06-27 17:05:58
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share GRAL The Nasdaq Global Select
- $888.9 m — in the second quarter of 2024 equal to $888.9 million, or the full remaining carrying v
- $560.0 million — Company had IPR&D intangible assets of $560.0 million. On June 27, 2024, Illumina disclosed t
- $420.0 million — PR&D intangible assets of approximately $420.0 million in connection with the Spin-Off, and su
Filing Documents
- gral-20240624.htm (8-K) — 26KB
- 0001628280-24-030355.txt ( ) — 151KB
- gral-20240624.xsd (EX-101.SCH) — 2KB
- gral-20240624_lab.xml (EX-101.LAB) — 22KB
- gral-20240624_pre.xml (EX-101.PRE) — 13KB
- gral-20240624_htm.xml (XML) — 3KB
06
Item 2.06 Material Impairments. On June 24, 2024, GRAIL, Inc. (the "Company" or "GRAIL") announced that its previously announced separation (the "Spin-Off") from Illumina, Inc. ("Illumina") was completed. In connection with the Spin-Off, the Company filed a Current Report on Form 8-K on June 3, 2024 to, among other things, file a final information statement, dated June 3, 2024, describing the Spin-Off and providing important information regarding the Company (the "Information Statement"). As disclosed in the Information Statement, due to the application of pushdown accounting, the Company's balance sheet includes goodwill and indefinite-lived intangible assets recognized by Illumina in connection with the acquisition of GRAIL in the third quarter of 2021. Goodwill represents the costs in excess of the fair value of net assets of GRAIL acquired by Illumina. Indefinite-lived intangible assets consist of GRAIL's in-process research and development ("IPR&D") and were measured by Illumina at fair value as of the closing date of the acquisition of GRAIL by Illumina. Further, as disclosed in the Information Statement, these goodwill and indefinite-lived intangible assets have been subject to impairment and may be subject to further impairment in the future. In connection with the foregoing, the Company expects to perform an interim impairment test for goodwill and indefinite-lived intangible assets. While the Company has not completed its interim impairment test, the Company estimates that it will recognize a goodwill impairment charge in the second quarter of 2024 equal to $888.9 million, or the full remaining carrying value of goodwill as of March 31, 2024. In addition, the Company estimates that it will recognize a significant impairment charge for IPR&D intangible assets in the second quarter of 2024. As of March 31, 2024, the Company had IPR&D intangible assets of $560.0 million. On June 27, 2024, Illumina disclosed that it expects to recognize an impairment char
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GRAIL, INC. Date: June 27, 2024 By: /s/ Abram Barth Name: Abram Barth Title: General Counsel and Corporate Secretary